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ScienceDirectTransition metal catalysts for the bioorthogonal
synthesis of bioactive agents
Melissa O. N. van de L’Islea,
Mari Carmen Ortega-Liebanaa and Asier Unciti-BrocetaAbstract
The incorporation of abiotic transition metal catalysis into the
chemical biology space has significantly expanded the tool kit
of bioorthogonal chemistries accessible for cell culture and
in vivo applications. A rich variety of homogeneous and het-
erogeneous catalysts has shown functional compatibility with
physiological conditions and biostability in complex environs,
enabling their exploitation as extracellular or intracellular fac-
tories of bioactive agents. Current trends in the field are
focusing on investigating new metals and sophisticated cata-
lytic devices and toward more applied activities, such as the
integration of subcellular, cell- and site-targeting capabilities or
the exploration of novel biomedical applications. We present
herein an overview of the latest advances in the field, high-
lighting the increasing role of transition metals for the
controlled release of therapeutics.
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Performing selective chemical modifications on bio-
molecules in their native conditions has challenged
chemists for decades. Along with the constraints of
adapting high-yielding reactions carried out in organicCurrent Opinion in Chemical Biology 2021, 61:32–42solvents at high temperatures to aqueous media and
lukewarmness, there is the essential requisite of pro-
curing high chemoselectivity in the presence of a com-
plex pool of functionalities. The field of bioorthogonal
chemistry arose in response to this challenge by devel-
oping water-compatible reactions between reactant
pairs with high reciprocal reactivity [1]. This has greatly
expanded the research space for chemists and biologists,
enabling to investigate and exploit previously unfeasible
chemical transformations in conditions compatible with
biomolecular structure, in vitro, in cells and in living
organisms (Figure 1a). This synthetic paradigm con-
tinues to grow and evolve by the needs and interests of
researchers from different areas [1,2].
Among the new trends in the field, one exciting path
taken by a number of laboratories have witnessed the
integration of concepts and tools from the fields of
transition metal catalysis, medicinal chemistry, and cell
delivery under the bioorthogonal banner. Early in-
cursions into the use of organometallic catalysts in living
cells to perform specific xenobiotic transformations d
rather than to directly elicit a pharmacological effect d
explored the intracellular cleavage of allylcarbamate
bonds using Ru [3] or Pd [4,5] catalysis (Figure 1b).
Streu and Meggers [3] reported the intracellular release
of Alloc-protected rhodamine 110 by an organometallic
Ru(II) complex in HeLa cells in 2006. Later, Yusop et al.
[4] and Unciti-Broceta et al. [5] proved this reaction
could also be performed by Pd nanoparticles (Pd-NPs)
captured at the surface of polystyrene beads (0.5 mm in
diameter) that possessed the capacity to enter the
cytoplasm of human cells [4,5]. Notably, these cell-
penetrating Pd-functionalized nanodevices had the
added capacity of mediating SuzukieMiyaura cross-
couplings, which was demonstrated inside cells with
the synthesis of a mitochondria-targeted fluorophore.
These early works sparked interest in the potential of
using transition metal catalysts (TMCs) as
bioorthogonal tools to unmask structures capable of
mediating biological activity (Figure 1b and c). Thus, in
2014, independent works from Li et al. [6] and Weiss
et al. [7,8] reported the capacity of Pd to mediate
depropargylation reactions and investigated its use to
control enzymatic activity (in cells) and to uncage
clinical anticancer drugs (out of cells), respectively. Inwww.sciencedirect.com
Figure 1
Overview of bioorthogonal methods and tools. (a) Classical click and bioorthogonal reactions. (b) Bioorthogonal TMC-triggered dealkylation reactions. (c)
Examples of TMC-activatable prodrugs of clinical anticancer agents. (d) Examples of homogeneous and heterogeneous TMC-based catalysts used in
bioorthogonal chemistry.
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Figure 2
Overview of organometallic complexes and reactions explored in bioorthogonal catalysis. (a) Organometallic complexes to mediate bond cleavage re-
actions. (b) Organometallic complexes to mediate C-C bond formation and isomerization reactions.
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Abiotic transition metals to make bioactive agents van de L’Isle et al. 35the same year, Sánchez et al. [9] and Volker et al. [10]
reported that Ru-mediated deallylations could also
trigger the uncaging of bioactive agents. Examples of
TMC-activatable bioactive precursors include prodrugs
of clinically used chemotherapeutics such as 5FU [7],
gemcitabine [8], doxorubicin [11], SN38 (active
metabolite of irinotecan [12]), or vorinostat [13]
(Figure 1c). Many other TMCs capable of performing
bioorthogonal reactions have emerged over the years
[14e21], which have expanded the tool kit of metals
and devices capable to release bioactive reagents or
initiate enzymatic catalysis in living systems
(Figure 1d).
Herein, we provide an up-to-date overview of the latest
advances on the development and application of ho-
mogeneous and heterogeneous TMCs as bioorthogonal
tools, with special emphasis on those devised to pro-
duce bioactive small molecules since 2018.Organometallic complexes
A diversity of organometallic complexes has been
investigated as bioorthogonal catalysts in recent years.
The modular synthesis of this class of compounds fa-
cilitates the exploration of different oxidation states and
multiple ligands to tune and optimize their physical,
chemical, and biological properties, for example, water
solubility, catalytic activity and productivity, cell pene-
trability, subcellular localization, and inherent toxicity.
This is exemplified in the works of Streu and Meggers
[3] and Volker et al. [10], which d after their early
exploration of Ru-mediated deallylations in cells [3] d
surveyed the use of quinolone-2-carboxylate ligands to
optimize the catalytic properties of Ru(II) complexes
under physiological conditions and in cells [10], result-
ing in improved catalysts’ turnover numbers and elimi-
nating the need of unnatural thiols as reaction additives
(Figure 2a). Similarly, the exploration of phosphine-
based ligands for the preparation of biocompatible
Pd(II) complexes, reported by Martinez-Calvo et al.
[22], led to the discovery of compounds capable of
mediating intracellular dealkylation reactions and the
incorporation of a ligand (bearing a pyrene ring) that
induced selective complex accumulation in the mito-
chondria (Figure 2a). Using a submonomer solid-phase
approach, Cherukaraveedu et al. [23] synthesized a li-
brary of N-heterocyclic carbeneePd complexes that
incorporated hydrophilic and lipophilic groups to
investigate catalytic efficacy. The glycine-linked catalyst
was the most robust catalyst of the series, being capable
of activating Pro-5FU (a bioorthogonal prodrug of 5FU
[7]) in cells and spheroids.
Conversely, other groups have focused on the devel-
opment of new caging strategies and linkers to control
the bioorthogonal release of bioactive agents by well-
established organometallic compounds. In thiswww.sciencedirect.comdirection, Lv et al. [24] designed O2-propargyl
diazeniumdiolates to control the release of NO mol-
ecules (natural metabolite that exerts antiproliferative
activity at high concentration) by Pd-mediated deal-
kylation chemistry (Figure 2a). The variety of alkyne-
bearing protecting groups that are labile to Pd cata-
lysts was supplemented with the development of a
thioether-directed cleavable linker by Stenton et al.
[25] (Figure 2a). This linker was used to construct an
antibodyedrug conjugate (ADC) capable of releasing
its cytotoxic cargo by Pd chemistry, specifically an
anti-HER2 nanobodyedoxorubicin conjugate that is
cleaved upon reaction with Pd(COD)Cl2. More
recently, the same group has reported that Pt com-
plexes (II and IV) can also cleave alkyne-bearing
masking groups (pentynoyl amide and N-propargyl
groups) in living systems and be used to release caged
drugs and cleave ADCs (Figure 2a) [26]. Of note, the
chemotherapeutic drug cisplatin (a Pt (II) complex)
was capable of activating Pro-5FU [7], resulting in
tumor shrinkage in a xenograft model in zebrafish only
when both drug and prodrug were added together
[26].
Along with bond cleavage reactions, Au- and Ru-based
organometallic complexes have been used to mediate
different bioorthogonal transformations in cells, such as
bond formation and isomerization reactions (Figure 2b).
Vidal et al. [27] showed the capacity of an Au(I) com-
plex (featuring an 1,3,5-triaza-7-phosphaadamantane
ligand) to promote the hydroarylation of a procoumar-
in substrate in cells to generate a highly fluorescent
fluorophore (Figure 2b). In this study, the use of 1,3,5-
triaza-7-phosphaadamantane and other water-soluble
ligands was investigated, with the former showing
optimal reactivity in cells and lower toxicity than the
others, showcasing the importance of the ligand to
generate a truly bioorthogonal organometallic complex.
Researchers have also shown that cyclometalated
Au(III) complexes can catalyze cysteine arylation re-
actions in peptides under physiological conditions
[28,29], a process that may play a role in the cytotoxic
effect of certain organogold compounds. Nonetheless,
as reported by Wenzel et al. [29], the selection of the
ligand is key to drive this cross-coupling reaction
toward the modification of certain zinc finger domains.
The authors found that selected Au(III) complexes
featuring bidentate C^N-donor ligands are optimal to
form adducts with the Cys residues of zinc finger pep-
tides (Cys2His2 type) and, subsequently, create a CeS
bond between the target peptide and the ligand by
reductive elimination. The possibility to direct this
cross-coupling process to specific sequences of biologi-
cally relevant proteins makes this reaction a promising
addition to the bioorthogonal toolbox [30]. Vidal et al.
[31] recently demonstrated that Ru(IV) complexes can
catalyze redox-neutral isomerization reactions in living
cells, enabling the intracellular transformation ofCurrent Opinion in Chemical Biology 2021, 61:32–42
36 Bioinorganic Chemistrynonbiological allylic alcohols into a,b-unsaturated ke-
tones (Figure 2b). This strategy was also used to
generate a,b-unsaturated ketones with strong Michael
acceptor character to deplete the cells from protective
nucleophilic thiols such as glutathione, which repre-
sents a new strategy to induce a biological effect
through a bioorthogonal process. Using the same metal,
Sabatino et al. [32] reported in the same year a
completely different approach to modulate cell biology
in a bioorthogonal manner. The authors designed a
masking group that is cleaved in two sequential stepsFigure 3
Overview of the modular design of ArMs used in cells and their reactivities. (a)
ArMs to mediate bond-cleavage reactions in cells.
Current Opinion in Chemical Biology 2021, 61:32–42triggered by a single Ru-mediated reaction: ring-closing
metathesis followed by drug release driven by the gen-
eration of an aromatic ring (Figure 2b). The so-called
‘close-to-release’ strategy performed best using the
water-soluble 2nd generation HoveydaeGrubbs catalyst
and is applicable to protect various functionalities [32].
Of note, caged umbelliferone was successfully released
using an artificial metathase (protein functionalized
with Ru complex previously developed by the same
group [15]) in E. coli. This distinct class of catalysts is
described in detail in the following section.Ru-based ArMs to mediate ring-closing metathesis in cells. (b) Ru-based
www.sciencedirect.com
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Metalloproteins developed in the laboratoryd so-called
artificial metalloenzymes (ArMs) d are becoming
essential biotechnology tools in research and industry
[33]. The opportunity of upgrading nonbiological TMCs
with enzyme-like substrate specificity and high
biocompatibility has recently inspired chemists to
explore ArMs for performing bioorthogonal catalytic re-
actions. Although several TMCs have been investigated
(e.g. Au, Rh, Ir [33]), Ru has been the main metal
explored to develop ArMs with the capacity to manu-
facture bioactive agents in cell culture [34e36]. The
earliest use of ArMs to mediate a bioorthogonal reaction
in cells was reported by Jeschek et al. [15] in 2016. In
this work, a derivative of the 2nd generation Hoveydae
Grubbs catalyst was conjugated to biotin, which acted as
an anchor to incorporate this TMC into streptavidin
(SAV) and thereby create an ArM with the capacity to
catalyze ring-closing metathesis (Figure 3a). Design of
an E. coli strain expressing SAV fused with the OmpA
signal peptide (SAVperi) enabled protein accumulation
in the cell periplasm. The ArM was formed in situ upon
addition of the Ruebiotin complex, endowing the cells
with metathesis activity as demonstrated by the syn-
thesis of umbelliferone. While the reaction yield was
modest, the authors demonstrated its improvement
through directed evolution, a method that also allowed
optimization for different substrates [15].
The assembly of ArMs to promote Ru-catalyzed
metathesis was also investigated by Eda et al. [34]
(Figure 3a). The goal of this work was to create an ArM
that was unaffected by intracellular thiols. To do so, they
exploited the high binding affinity of the deep hydro-
phobic pockets of albumin for aminocoumarin to anchor
a Ru catalyst into glycosylated human serum albumin.
This glycosylated ArM, equipped with Ru(II) and
modified with N-glycan targeting moieties, mediated
ring-closing metathesis of a range of diene compounds,
including a precursor of umbelliprenin (natural product
with anticancer properties). In this approach, cancer
cells are preferentially targeted by the glycans of the
ArMs, facilitating the selective synthesis of anticancer
agents in malignant cells [34].
A biotinylated derivative of the catalyst developed by
Volker et al. [10] has also been used to build artificial
deallylases (Figure 3b) [35,36]. Okamoto et al. [35]
functionalized SAV with a module that promoted cell
penetration (poly-arginine functionality) and a Ru(II)
catalyst to catalyze the intracellular uncaging of the
thyroid hormone triiodothyronine. This bioactive
molecule was generated in HEK-293T cells transfected
with a hormone-responsive gene switch, thereby
inducing the expression of a secreted NanoLuc lucif-
erase [35]. In a different strategy, Szponarski et al. [36]
used a dimeric SAV to bind the protein onto the surfacewww.sciencedirect.comof C. reinhardtii (via membrane protein conjugation with
a biotinylated reagent) followed by anchoring a Ru(II)e
biotin complex to facilitate the site-selective extracel-
lular release of aminocoumarin (Figure 3b).Nanodevices
As discussed in the introduction, the first example of a
miniaturized device able to perform artificial chemis-
tries in cells was reported by Yusop et al. [4] in 2011,
who used polystyrene-based supports of approx. 0.5 mm
in diameter functionalised with Pd-NPs to mediate
deallylation and Suzuki reactions in the cell cytoplasm.
Subsequent studies by other groups were addressed to
further the understanding of how to control the activity
and localization of TMCs through nanodevice design. In
2015, Tonga et al. [14] developed a new design based on
the use of Au-NP cores and self-assembling monolayers
to facilitate the incorporation of hydrophobic Ru and Pd
complexes within the lipophilic monolayer of the de-
vices. By sterically blocking their surface with macro-
cyclic cucurbiturils bound onto supramolecular anchors
tethered to the so-called nanozymes, they achieved
bioorthogonal regulation of TMC activity: addition of a
guest molecule (1-adamantylamine) resulted in the
displacement of the anchoring groups from the hosting
pocket of the cucurbiturils, thus freeing the nanozyme
surface and enabling the entry of prodyes and prodrugs
to undergo dealkylation reactions. Harnessing the
reversible photoisomerization of azobenzene switches
and the capacity of b-cyclodextrin to host trans-
azobenzene but not cis-azobenzene, Wang et al. [37]
developed a light-controlled bioorthogonal catalytic
system based on mesoporous silica nanoparticles func-
tionalized with Pd-NPs, complexed with azobenzene
groups and superficially caged with b-cyclodextrins.
Alike the natural allosteric regulation of an enzyme,
catalytic activity was controlled in a reversible manner
by light: activation under UV light and deactivation
under visible light. Its applicability in cells was shown
with the synthesis of two fluorescent probes d by
dealkylation and Suzuki reactionsd and the conversion
of Pro-5FU into cytotoxic 5FU.
Following on from his original work on nanozymes, the
Rotello lab has continued exploring alternative chem-
ical motifs at the surface of this class of nanodevices to
dictate intracellular or extracellular nanozyme locali-
zation [38] and to determine the effect of hard and soft
protein coronas on the catalytic activity of the nano-
zymes [39]. This last study showed that hard ‘irre-
versible’ coronas sterically block the TMC activity of
the nanozymes, while being restored after endosomal
cell entry and proteolytic degradation, thereby offering
a method to confine the bioorthogonal manufacture of
xenobiotics to the intracellular space. Other re-
searchers such as Destito et al. [40] and Martinez et al.
[41] have focused their efforts on improving theCurrent Opinion in Chemical Biology 2021, 61:32–42
38 Bioinorganic Chemistryproductivity of bioorthogonal Pd catalysis through the
design of different kinds of nanodevices. Destito et al.
[40] developed hollow silica microspheres (0.5 mm in
diameter) as supports to protect Pd-NPs from passiv-
ation and poisoning by biomolecules. These devices
were highly efficient in performing depropargylation
reactions in biorelevant aqueous media and cells. More
recently, Martinez et al. [41] reported a water
compatible coreeshell Pd/metaleorganic
framework nanocomposite that promoted depro-
pargylations to activate different prodyes in cells and
3D spheroids. Cells loaded with these nanodevices
were able to process sequential batches of reacting
probes (up to 4 cycles), first example of reusable ‘cat-
alytic cells’.
One of the key advantages of using heterogeneous or
encapsulated TMCs into nanoscale carriers is the po-
tential to achieve intratumoral accumulation in vivo
through the enhanced permeability and retention effect.Figure 4
Nanodevices, microdevices, and millidevices used to generate bioactive compo
agents in cells. (b) Microdevices and millidevicesanodevices to make or rele.
Current Opinion in Chemical Biology 2021, 61:32–42Miller et al. [17] demonstrated this using poly(lactic-co-
glycolic acid)-polyethyleneglycol (PLGA-PEG) poly-
meric micelles to encapsulate PdeCl2 (TFP)2 and
deliver the catalyst into tumor xenografts. Separate
administration of an Alloc-protected prodrug of doxoru-
bicin [10] (also encapsulated in PLGA-PEG polymeric
micelles) achieved site-selective delivery of both for-
mulations, which upon reaction elicited anticancer ac-
tivity in a fibrosarcoma model in mice. The versatility of
this approach was expanded in vivo with the delivery of
an encapsulated prodrug of an extremely potent toxin
such as monomethyl auristatin E [42]. Using a different
targeting concept, Hoop et al. [43] also reported a
strategy to achieve site-selective delivery of Pd catalysts
in culture and in vivo by creating nanowires composed of
magnetic Fe and catalytic Pd. Magnetic fields were used
to localize the devices to predefined areas of a cancer cell
culture and selectively kill the targeted cell population
by activation of Pro-5FU [7] into 5FU. In a proof-of-
concept assay, the authors showed the in vivo potentialunds in cells and organisms. (a) Nanodevices to make or release bioactive
www.sciencedirect.com
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shrinkage in a xenograft model directly inoculated with
the magnetic nanocatalysts.
Increasing the delivery efficiency of therapeutics to
disease sites, thereby preventing damage to healthy
tissues, is one of the main goals of the nanomedicine
field. Beyond the aforementioned studies, which
addressed site-selective targeting by physical methods,
a recent study by Sancho-Alberto et al. [44] has shown
the potential of using intercellular trafficking pathways
to carry catalytic nanoreactors to specific cancer cells.
The authors developed a bioinorganic hybrid nanoplat-
form for targeted bioorthogonal chemistry by integrating
the targeting capabilities of cancer-derived exosomes
and the catalytic properties of Pd nanosheets [44].
These Pd-functionalized vesicles showed preferential
tropism for their parent cells and mediated the intra-
cellular manufacture of the anticancer drug panobino-
stat in their progenitor cells but not in other cell lines
(Figure 4a). Du et al. [45] proposed a different approach
to achieve site-selective delivery of TMCs. The authors
supported Pd-NPs on mesoporous silica nanoparticles
and cloaked them with neutrophil membranes to be
trafficked to sites of inflammation. Notably, the catalyst
surface was modified with cinchona alkaloids to promote
asymmetric transfer hydrogenation in the presence of
hydrogen donors (sodium formate). Enantioselective
synthesis of S-ibuprofen (active enantiomer) from a
nonchiral precursor was carried out in vivo, alleviating
the inflammation of injured mouse paw.
Alternative transition metals such as Cu, Au, and Fe
have recently been used in the development of
bioorthogonal catalytic nanodevices. Lui et al. [20] used
single-chain polymeric nanoparticles modified with
metal-complexing ligands as polymeric scaffolds to bind
Pd(II) or Cu(I) ions. Of note, they showed that dime-
thylpropargyl groups were rapidly cleaved by Cu(I)-
based single-chain polymeric nanoparticles in cells,
chemistry that was later modified by Wang et al. [21] to
catalyze the bioorthogonal cleavage of ADCs with Cu
complexes. Huang et al. [46] encapsulated Cu-NPs in
cross-linked lipoic acid nanoparticles of various mor-
phologies to perform CuAAC reactions in cells. Inter-
estingly, devices with a prolate spheroid shape were
taken up faster by cells and catalyzed the synthesis of a
triazole-containing anticancer agent (drug synthesis
strategy first reported by Clavadetscher et al. [18],
Figure 4a). Wang et al. [47] built a heterogeneous Cu
catalyst on a metaleorganic framework decorated with
lipophilic cations to perform CuAAC reactions in the
mitochondria of cancer cells, where they mediated the
synthesis of an polyphenolic analog of the same triazole-
containing bioactive agent (Figure 4a).
Introducing additional control into bioorthogonal nano-
reactors, Kumar et al. [48] reported that the entrapmentwww.sciencedirect.comof plasmonic Au nanospheroids in aminated silica
nanoparticles can efficiently harness NIR light to
accelerate catalysis and allow remote control of catalytic
activity in living cells. Through an alternative photo-
catalytic strategy, Mazzei et al. [49] proposed the use of
Au-NPs functionalized with alkanethiols bearing 1,4,7-
triazacyclononane headgroups (positively charged
under physiological conditions) to encapsulate nega-
tively charged flavins. Under UV irradiation in the
presence of 2-(N-morpholino)ethanesulfonic acid
(electron donor), these nanodevices were capable of
reducing a Pt (IV) prodrug into the Pt (II) anticancer
drug cisplatin, although the compatibility of these
photocatalytic nanozymes in cells is yet to be demon-
strated. Of note, in this approach, the role of the metals
are inverted: Au-NPs act as scaffolds to build the
nanozymes that entrap the flavins, which are the
photocatalysts, and the Pt (IV) species are the reaction
substrates. Using thermal control instead, Cao-Milan
et al. [50] developed a thermoresponsive nanozyme by
incorporating supramolecular assemblies of Fe(III)-
porphyrins (FeTPP). At low temperature, the FeTPP
complexes aggregate and become catalytically inactive,
while the FeTPP disassembles upon heating throughout
the lipidic monolayer, enabling their catalytic properties
in a reversible manner. Its applicability was demon-
strated by reducing a prodrug to release the antibiotic
moxifloxacin and effectively killing E. coli bacterial bio-
films (Figure 4a).Extracellular microdevices and millidevices
In 2014, Weiss et al. [7,8] reported the use of extra-
cellular microdevices (TentaGel resins) to entrap Pd-
NPs and mediate bioorthogonal drug activation in cell
culture. The authors showed that the Pd-mediated
cleavage of propargyl groups took place faster than
that of allyl groups and proved their in vivo functional
compatibility in zebrafish. This solid-supported
approach was later expanded to host other metal nano-
particles such as Cu (Clavadetscher et al. [18]) or Au
(Perez-Lopez et al. [19]) to make anticancer agents by
CuAAC and depropargylation reactions, respectively, or
to mediate extracellular Pd-promoted Suzuki reactions
to assemble a multikinase inhibitor [51]. More recently,
Bray et al. [11] studied the importance of the size of the
microspheres and found that 30 mm in diameter was
optimal for Pd loading capacity and catalytic efficacy.
This size was also suitable for intratumoral implantation
into an orthotopic prostate cancer in mice. Notably, the
authors showed thatd because of the echogenic nature
of the metal d the insertion of the implants could be
monitored by ultrasound-guided imaging (a standard
clinical procedure). By tumor resection and monitoring
ex vivo, the authors proved the activation of a fluorescent
probe and a prodrug of doxorubicin (oPOBC-Dox,
Figure 1c) and that the devices remained unaltered and
catalytically active after 21 days in the tumor. AdamCurrent Opinion in Chemical Biology 2021, 61:32–42
40 Bioinorganic Chemistryet al. [12] later showed that these devices were capable
to activate simultaneously two prodrugs in cancer cell
culture, Pro-SN38 and Pro-5FU (Figure 1c), cytotoxic
agents clinically used in combination therapy. Toward a
different application, Plunk et al. [52] proposed the use
of bioorthogonal Pd chemistry to induce local suppres-
sion of the innate immunological response after organ
transplants. Although still in an early stage, they re-
ported the use of Pd microspheres to activate a
bioorthogonal prodrug of resatorvid (Figure 4b), a toll-
like receptor 4 inhibitor in clinical development [52].
The use of millimeter-sized scaffold materials to host Pd
catalysts has also been explored. Torres-Sánchez et al.
[53] manufactured implants by depositing Pd onto ti-
tanium scaffolds using different techniques. These de-
vices showed high biocompatibility in cancer cell culture
and the capacity to activate a prodrug of the anticancer
drug vorinostat (Pro-SAHA [13], Figure 1c). Toward the
development of implantable catalytic systems that are
inherently biodegradable, Perez-López et al. [54] re-
ported the use of natural hydrogels (agarose and algi-
nate) to entrap ultrathin Pd nanosheets in solid
polymeric frameworks that allow the internal diffusion
of small molecules (Figure 4b). This strategy provides a
catalytic system to temporarily promote local
bioorthogonal reactions, which would be ideal for short-
term applications (e.g. neoadjuvant chemotherapy). Of
note, the authors designed a Pd-activatable prodrug of
the anticancer drug paclitaxel (Figure 4b) using a
protecting group tailored made for aliphatic OH.Conclusions
The use of metal catalysts in biomedical research has
continuously grown during the last decade. Alongside
strategies that exploit TMCs to promote the catalytic
transformation of cell substrates and achieve a direct
biological effect, so-called catalytic metallodrugs
[55,56], applications have greatly expanded toward the
opposite direction, that is, the use of abiotic metals as
bioorthogonal catalysts to mediate new-to-life reactions
in a safe manner. The toolbox of TMCs that shows
innocuity and functional compatibility with living cells
and organisms is rapidly increasing, allowing researchers
to explore multiple chemical processes and biological
applications, including the bioorthogonal synthesis of a
variety of pharmacological agents. This rapidly evolving
research topic represents nowadays a key driver in
chemical biology, as seen by the continued appearance
of innovative works, even during the preparation of this
review [57e59].
One of the key aspects of this research is the use of
homogeneous versus heterogeneous catalysts, a choice
that is made based on the goals of the study. The first
ones have the advantage of increasing catalyst pro-
ductivity and can be incorporated into metalloproteinsCurrent Opinion in Chemical Biology 2021, 61:32–42to improve their biocompatibility and substrate speci-
ficity. On the other hand, heterogeneous TMC devices
can modulate best the fate of the catalyst in vivo and act
either as a targeted or implantable bioorthogonal
reactor for therapeutic applications. While the latest
advances in this direction have shown great promise to
progress the use of bioorthogonal TMCs into a bona fide
medical alternative, future developments will need to
focus further on fine-tuning target selectivity and
improving long-lasting catalytic activity in vivo.
Shielding the TMCs from direct contact with inter-
cellular/intracellular environments will likely be
essential to prolong the catalyst’s lifespan and thereby
achieve bioactive levels of drug release at the disease
site. Importantly, the development of new methods
and TMC-labile sensors will be vital to monitor catalyst
activity in vivo, as a proxy to measure its productivity
and assist adequate matching with (pro)drugs that
display the right level of activity. Combined adminis-
tration of catalytic devices that display high in vivo
productivity and a precursor of an ultrapotent cytotoxic
agent could generate supratherapeutic drug levels that
could distribute to healthy organs and cause harm. On
the contrary, low-productive catalysts should not be
combined with prodrugs of chemotherapeutics of low-
to-moderate activity, as this strategy will likely
generate local levels of drug below the therapeutic
threshold. All these aspects will need to be confronted
on the pathway from preclinical research to clinical
development. The success to translate the use of
TMCs as bioorthogonal medical devices will depend on
our capacity to develop strategies and methods that
address them. The challenge is set.Declaration of competing interest
The authors declare that they have no known competing
financial interests or personal relationships that could
have appeared to influence the work reported in this
article.
Acknowledgements
The authors thank H2020 Marie Skłodowska-Curie actions for funding
through grants THERACAT (MSCA-ITN-2017-765497) and GOLDEN
(MSCAeIFe2018-841990).
References
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
 of outstanding interest
1. Devaraj NK: The future of bioorthogonal chemistry. ACS Cent
Sci 2018, 4:952–959.
2. Li J, Chen PR: Development and application of bond cleavage
reactions in bioorthogonal chemistry. Nat Chem Biol 2016, 12:
129–137.
3

. Streu C, Meggers E: Ruthenium-induced allylcarbamate
cleavage in living cells. Angew Chem Int Ed 2006, 45:
5645–5648.www.sciencedirect.com
Abiotic transition metals to make bioactive agents van de L’Isle et al. 41First example of Ru-mediated deprotection in cells using organome-
tallic catalysts.
4

. Yusop RM, Unciti-Broceta A, Johansson EMV, Sanchez-
Martin RM, Bradley M: Palladium-mediated intracellular
chemistry. Nat Chem 2011, 3:239–243.
First example of Pd-mediated deprotection and Suzuki–Miyaura cross-
coupling in cells using Pd-functionalized nanodevices.
5. Unciti-Broceta A, Johansson EMV, Yusop RM, Sanchez-
Martin RM, Bradley M: Synthesis of polystyrene microspheres
and functionalization with Pd-0 nanoparticles to perform
bioorthogonal organometallic chemistry in living cells. Nat
Protoc 2012, 7:1207–1218.
6

. Li J, Yu JT, Zhao JY, Wang J, Zheng SQ, Lin SX, Chen L,
Yang MY, Jia S, Zhang XY, et al.: Palladium-triggered depro-
tection chemistry for protein activation in living cells. Nat
Chem 2014, 6:352–361.
First example of the use of TMCs to regulate intracellular enzymatic
activity using Pd complexes.
7

. Weiss JT, Dawson JC, Macleod KG, Rybski W, Fraser C, Torres-
Sanchez C, Patton EE, Bradley M, Carragher NO, Unciti-
Broceta A: Extracellular palladium-catalysed dealkylation of 5-
fluoro-1-propargyl-uracil as a bioorthogonally activated
prodrug approach. Nat Commun 2014, 5:3277.
First example of the use of TMCs to convert a inactive precursor (Pro-
5FU) into an active cytotoxic drug (5FU) using Pd-microspheres in
cancer cell culture.
8. Weiss JT, Dawson JC, Fraser C, Rybski W, Torres-
Sanchez C, Bradley M, Patton EE, Carragher NO, Unciti-
Broceta A: Development and bioorthogonal activation of
palladium-labile prodrugs of gemcitabine. J Med Chem
2014, 57:5395–5404.
9. Sanchez MI, Penas C, Vazquez ME, Mascarenas JL: Metal-
catalyzed uncaging of DNA-binding agents in living cells.
Chem Sci 2014, 5:1901–1907.
10. Volker T, Dempwolff F, Graumann PL, Meggers E: Progress
towards bioorthogonal catalysis with organometallic com-
pounds. Angew Chem Int Ed 2014, 53:10536–10540.
11

. Bray TL, Salji M, Brombin A, Perez-Lopez AM, Rubio-Ruiz B,
Galbraith LCA, Patton EE, Leung HY, Unciti-Broceta A: Bright
insights into palladium-triggered local chemotherapy. Chem
Sci 2018, 9:7354–7361.
Demonstration that Pd-microdevices are echogenic and can be inser-
ted in tumors with high precision by ultrasound-guided injection.
12. Adam C, Perez-Lopez AM, Hamilton L, Rubio-Ruiz B, Bray TL,
Sieger D, Brennan PM, Unciti-Broceta A: Bioorthogonal
uncaging of the active metabolite of irinotecan by palladium-
functionalized microdevices. Chemistry-A European J 2018,
24:16783–16790.
13. Rubio-Ruiz B, Weiss JT, Unciti-Broceta A: Efficient palladium-
triggered release of vorinostat from a bioorthogonal precur-
sor. J Med Chem 2016, 59:9974–9980.
14

. Tonga GY, Jeong YD, Duncan B, Mizuhara T, Mout R, Das R,
Kim ST, Yeh YC, Yan B, Hou S, Rotello VM: Supramolecular
regulation of bioorthogonal catalysis in cells using
nanoparticle-embedded transition metal catalysts. Nat Chem
2015, 7:597–603.
Development of modular nanozymes capable of hosting different lipo-
philic TMCs and mediate dealkylations in cells under supramolecular
control.
15

. Jeschek M, Reuter R, Heinisch T, Trindler C, Klehr J, Panke S,
Ward TR: Directed evolution of artificial metalloenzymes for
in vivo metathesis. Nature 2016, 537:661–665.
First example of a bioorthogonal metalloenzyme capable of catalyzing
artificial chemical reactions (metathesis) in cells (E. coli).
16. Tomas-Gamasa M, Martinez-Calvo M, Couceiro JR,
Mascarenas JL: Transition metal catalysis in the mitochondria
of living cells. Nat Commun 2016, 7:12538.
17

. Miller MA, Askevold B, Mikula H, Kohler RH, Pirovich D,
Weissleder R: Nano-palladium is a cellular catalyst for in vivo
chemistry. Nat Commun 2017, 8:15906.
First demonstration of Pd-mediated prodrug activation in cancer mouse
models (fibrosarcoma).www.sciencedirect.com18

. Clavadetscher J, Hoffmann S, Lilienkampf A, Mackay L,
Yusop RM, Rider SA, Mullins JJ, Bradley M: Copper catalysis in
living systems and in situ drug synthesis. Angew Chem Int Ed
2016, 55:15662–15666.
First use of Cu-mediated drug synthesis in cell culture.
19

. Perez-Lopez AM, Rubio-Ruiz B, Sebastian V, Hamilton L,
Adam C, Bray TL, Irusta S, Brennan PM, Lloyd-Jones GC,
Sieger D, et al.: Gold-triggered uncaging chemistry in living
systems. Angew Chem Int Ed 2017, 56:12548–12552.
First use of Au-mediated prodrug activation in cell culture and hetero-
geneous uncaging chemistry in the brain of zebrafish.
20. Liu YL, Pujals S, Stals PJM, Paulohrl T, Presolski SI, Meijer EW,
Albertazzi L, Palmans ARA: Catalytically active single-chain
polymeric nanoparticles: exploring their functions in com-
plex biological media. J Am Chem Soc 2018, 140:3423–3433.
21. Wang X, Liu YJ, Fan XY, Wang J, Ngai WSC, Zhang H, Li JF,
Zhang G, Lin J, Chen PR: Copper-triggered bioorthogonal
cleavage reactions for reversible protein and cell surface
modifications. J Am Chem Soc 2019, 141:17133–17141.
22. Martinez-Calvo M, Couceiro JR, Destito P, Rodriguez J,
Mosquera J, Mascarenas JL: Intracellular deprotection re-
actions mediated by palladium complexes equipped with
designed phosphine ligands. ACS Catal 2018, 8:6055–6061.
23. Cherukaraveedu D, Cowling PT, Birch GP, Bradley M, Annamaria
Lilienkampf A: Solid-phase synthesis of biocompatible N-het-
erocyclic carbene–Pd catalysts using a sub-monomer
approach. Org Biomol Chem 2019, 17:5533–5537.
24. Lv T, Wu JB, Kang FH, Wang TT, Wan BH, Lu JJ, Zhang YH,
Huang ZJ: Synthesis and evaluation of O-2-Derived diaze-
niumdiolates activatable via bioorthogonal chemistry re-
actions in living cells. Org Lett 2018, 20:2164–2167.
25

. Stenton BJ, Oliveira BL, Matos MJ, Sinatra L, Bernardes GJL:
A thioether-directed palladium-cleavable linker for targeted
bioorthogonal drug decaging. Chem Sci 2018, 9:4185–4189.
First example of TMC-mediated cleavage of ADC.
26. Oliveira BL, Stenton BJ, Unnikrishnan VB, de Almeida CR,
Conde J, Negrao M, Schneider FSS, Cordeiro C, Ferreira MG,
Caramori GF, et al.: Platinum-triggered bond-cleavage of
pentynoyl amide and N-propargyl handles for drug-activa-
tion. J Am Chem Soc 2020, 142:10869–10880.
27. Vidal C, Tomas-Gamasa M, Destito P, Lopez F, Mascarenas JL:
Concurrent and orthogonal gold (I) and ruthenium (II) catal-
ysis inside living cells. Nat Commun 2018, 9:1913.
28. Kung KK, Ko HM, Cui JF, Chong HC, Leung YC, Wong MK:
Cyclometalated gold(III) complexes for chemoselective
cysteine modification via ligand controlled C–S bond-
forming reductive elimination. Chem Commun 2014, 50:
11899–11902.
29. Wenzel MN, Bonsignore R, Thomas SR, Bourissou D, Barone G,
Casini A: Cyclometalated AuIII complexes for cysteine aryla-
tion in zinc finger protein domains: towards controlled
reductive elimination. Chem Eur J 2019, 25:7628–7634.
30. Thomas SR, Bonsignore R, Sánchez Escudero J, Meier-
Menches SM, Brown CM, Wolf MO, Barone G, Luk LYP, Casini A:
Exploring the chemoselectivity towards cysteine arylation by
cyclometallated AuIII compounds: new mechanistic insights.
Chembiochem 2020, https://doi.org/10.1002/cbic.202000262.
31. Vidal C, Tomas-Gamasa M, Gutierrez-Gonzalez A,
Mascarenas JL: Ruthenium-catalyzed redox isomerizations
inside living cells. J Am Chem Soc 2019, 141:5125–5129.
32

. Sabatino V, Rebelein JG, Ward TR: Close-to-Release": spon-
taneous bioorthogonal uncaging resulting from ring-closing
metathesis. J Am Chem Soc 2019, 141:17048–17052.
First example of TMC-promoted prodrug uncaging that is triggered by a
ring-closing metathesis.
33. Tanaka K, Vong K: Unlocking the therapeutic potential of
artificial metalloenzymes. Proc Jpn Acad Ser B Phys Biol Sci
2020, 96:79–94.
34. Eda S, Nasibullin I, Vong K, Kudo N, Yoshida M, Kurbangalieva A,
Tanaka K: Biocompatibility and therapeutic potential ofCurrent Opinion in Chemical Biology 2021, 61:32–42
42 Bioinorganic Chemistryglycosylated albumin artificial metalloenzymes. Nat Catalysis
2019, 2:780–792.
35

. Okamoto Y, Kojima R, Schwizer F, Bartolami E, Heinisch T,
Matile S, Fussenegger M, Ward TR: A cell-penetrating artificial
metalloenzyme regulates a gene switch in a designer
mammalian cell. Nat Commun 2018, 9:1943.
First example of the use of ArM and inactive small molecules to release
a hormone and control gene expression in cells.
36. Szponarski M, Schwizer F, Ward TR, Gademann K: On-cell
catalysis by surface engineering of live cells with an artificial
metalloenzyme. Commun Chem 2018, 1:84.
37. Wang FM, Zhang Y, Du Z, Ren JS, Qu XG: Designed hetero-
geneous palladium catalysts for reversible light-controlled
bioorthogonal catalysis in living cells. Nat Commun 2018, 9:
1209.
38. Das R, Landis RF, Tonga GY, Cao-Milan R, Luther DC,
Rotello VM: Control of intra- versus extracellular bio-
orthogonal catalysis using surface-engineered nanozymes.
ACS Nano 2019, 13:229–235.
39. Zhang X, Liu Y, Gopalakrishnan S, Castellanos-Garcia L, Li G,
Malassiné M, Uddin I, Huang R, Luther DC, Vachet RW,
Rotello VM: Intracellular activation of bioorthogonal nano-
zymes through endosomal proteolysis of the protein corona.
ACS Nano 2020, 14:4767–4773.
40. Destito P, Sousa-Castillo A, Couceiro JR, Lopez F, Correa-
Duarte MA, Mascareñas JL: Hollow nanoreactors for Pd-
catalyzed Suzuki-Miyaura coupling and O-propargyl cleavage
reactions in bio-relevant aqueous media. Chem Sci 2019, 10:
2598–2603.
41. Martínez R, Carrillo-Carrión C, Destito P, Alvarez A, Tomás-
Gamasa M, Pelaz B, Lopez F, Mascareñas JL, del Pino P: Core-
shell palladium/MOF platforms as diffusion-controlled nano-
reactors in living cells and tissue models. Cell Reports Phys
Sci 2020, 1:100076.
42. Miller MA, Mikula H, Luthria G, Li R, Kronister S, Prytyskach M,
Kohler RH, Mitchison T, Weissleder R: Modular nanoparticulate
prodrug design enables efficient treatment of solid tumors
using bioorthogonal activation. ACS Nano 2018, 12:
12814–12826.
43. Hoop M, Ribeiro AS, Rosch D, Weinand P, Mendes N, Mushtaq F,
Chen XZ, Shen Y, Pujante CF, Puigmarti-Luis J, et al.: Mobile
magnetic nanocatalysts for bioorthogonal targeted cancer
therapy. Adv Funct Mater 2018, 28:1705920.
44

. Sancho-Albero M, Rubio-Ruiz B, Perez-Lopez AM, Sebastian V,
Martin-Duque P, Arruebo M, Santamaria J, Unciti-Broceta A:
Cancer-derived exosomes loaded with ultrathin palladium
nanosheets for targeted bioorthogonal catalysis. Nat Catal-
ysis 2019, 2:864–872.
First example of the use of intercellular trafficking systems to deliver
TMCs (Pd nanosheets) and mediate bioorthogonal reactions (including
prodrug activation) to specific cancer cell populations.
45

. Du Z, Liu C, Song H, Scott P, Liu Z, Ren J, Qu X: Neutrophil-
membrane-directed bioorthogonal synthesis of
inflammation-targeting chiral drugs. Inside Chem 2020, 6:
2060–2072.
First chiral synthesis of the active enantiomer of a drug (S-ibuprofen) by
targeted bioorthogonal nanocatalysts (neutrophil membrane-cloaked
devices contaning Pd-NP) at sites of inflammation.Current Opinion in Chemical Biology 2021, 61:32–4246. Huang JS, Wang L, Zhao PX, Xiang FQ, Liu J, Zhang SY:
Nanocopper-doped cross-linked lipoic acid nanoparticles for
morphology-dependent intracellular catalysis. ACS Catal
2018, 8:5941–5946.
47. Wang FM, Zhang Y, Liu ZW, Du Z, Zhang L, Ren JS, Qu XG:
A biocompatible heterogeneous MOF-Cu catalyst for in vivo
drug synthesis in targeted subcellular organelles. Angew
Chem Int Ed 2019, 58:6987–6992.
48. Kumar A, Kumar S, Kumari N, Lee SH, Han J, Michael IJ, Cho YK,
Lee IS: Platonically coupled nanoreactors for NIR-light-
mediated remote stimulation of catalysis in living cells. ACS
Catal 2019, 9:977–990.
49. Mazzei LF, Martínez A, Trevisan L, Rosa-Gastaldo D,
Cortajarena AL, Mancin F, Salassa L: Toward supramolecular
nanozymes for the photocatalytic activation of Pt(iv) anti-
cancer prodrugs. Chem Commun 2020, 56:10461–10464.
50. Cao-Milan R, Gopalakrishnan S, He LD, Huang R, Wang LS,
Castellanos L, Luther DC, Landis RF, Makabenta JMV, Li CH,
et al.: Thermally gated bio-orthogonal nanozymes with
supramolecularly confined porphyrin catalysts for antimi-
crobial uses. Inside Chem 2020, 6:1113–1124.
51. Indrigo E, Clavadetscher J, Chankeshwara SV, Lilienkampf A,
Bradley M: Palladium-mediated in situ synthesis of an anti-
cancer agent. Chem Commun 2016, 52:14212–14214.
52. Plunk MA, Alaniz A, Olademehin OP, Ellington TL, Shuford KL,
Kane RR: Design and catalyzed activation of tak-242
prodrugs for localized inhibition of TLR4-induced inflamma-
tion. ACS Med Chem Lett 2020, 11:141–146.
53. Torres-Sanchez C, Perez-Lopez AM, Alqahtani MN, Unciti-
Broceta A, Rubio-Ruiz B: Design and manufacture of func-
tional catalyst-carrier structures for the bioorthogonal acti-
vation of anticancer agents. New J Chem 2019, 43:1449–1458.
54. Pérez-López AM, Belén Rubio-Ruiz B, Valero T, Contreras-
Montoya R, Álvarez de Cienfuegos L, Sebastián V, Santamaría J,
Unciti-Broceta A: Bioorthogonal uncaging of cytotoxic pacli-
taxel through Pd nanosheet-hydrogel frameworks. J Med
Chem 2020, 63:9650–9659.
55. Soldevila-Barreda JJ, Romero-Canelón I, Habtemariam A,
Sadler PJ: Transfer hydrogenation catalysis in cells as a new
approach to anticancer drug design. Nat Commun 2015, 6:
6582.
56. Yu Z, Cowan JA: Catalytic metallodrugs: substrate-selective
metal catalysts as therapeutics. Chem Eur J 2017, 23:
14113–14127.
57. Huang R, Li C-H, Cao-Milan R, He LD, Makabenta JM, Zhang X,
Yu E, Rotello VM: Polymer-based bioorthogonal nano-
catalysts for the treatment of bacterial biofilms. J Am Chem
Soc 2020, 142:10723–10729.
58. Miguel-Ávila J, Tomás-Gamasa M, Mascareñas JL: Intracellular
ruthenium-promoted (2+2+2) cycloadditions. Angew Chem Int
Ed 2020, 59:17628–17633.
59. Vong K, Yamamoto T, Chang T-C, Tanaka K: Bioorthogonal
release of anticancer drugs via gold-triggered 2-
alkynylbenzamide cyclization. Chem Sci 2020, 11:
10928–10933, https://doi.org/10.1039/D0SC04329J.www.sciencedirect.com
